Supplementary Figure 22 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Key Points

• Higher systemic short-chain fatty acid levels at 100 and 180 days post-infusion correlate with better treatment response in myeloma patients.
• The analysis compares SCFA levels in patients achieving complete response versus those who do not, indicating a potential predictive value.
• Evaluation focused on patients with multiple myeloma receiving CAR T-cell therapy, emphasizing metabolic involvement in treatment outcomes.
• These findings highlight the importance of metabolic markers in optimizing CAR T-cell therapy effectiveness in myeloma.